Excel Industries Q2 & H1 FY26 Earnings Call Transcript
Excel Industries releases transcript of Q2 & H1 FY26 earnings call. New specialty chemical contract, biocide capacity expansion, R&D center on track. Revenue at ₹270 crore for the quarter, ₹580 crore for H1.
The announcement includes details of a new contract and capacity expansion, which are positive developments that could have a medium impact on the company's future performance.
The announcement primarily conveys factual information regarding the earnings call, financial results, and business developments. While some developments are positive, the overall tone is neutral and informative.
* Excel Industries held an earnings conference call on 14 Nov 2025 for Q2 & H1 FY26, transcript available on the company website. * Ravi Shroff, MD, mentioned a binding term sheet signed for contract manufacturing of a specialty chemical with a reputed Indian company, spanning five years. This involves setting up a new production line expected by June 2026, with an investment of ₹40 crore, expected to generate annual revenue of ₹35 crore to ₹40 crore (excluding raw material costs) and is EBITDA accretive. A trade advance of ₹25 crore will be received from the customer. * Capacity expansion of a key biocide product was commissioned in October 2025, with initial supplies commenced under a long-term supply arrangement with a multinational company. * The new R&D center is on track to become operational in Q3 FY26. * Devendra Dosi, CFO, reported standalone revenues of ₹270 crore for the quarter versus ₹310 crore in Q1 FY26, with a 17.7% export contribution. EBITDA stood at ₹30 crore, and profit after tax was ₹19 crore. * For H1 FY26, net operating revenue was ₹580 crore, a 9% increase over H1 FY25. EBITDA for H1 FY26 was ₹72 crore, and profit after tax stood at ₹52 crore. * The company expects 13% to 15% EBITDA margins for the full year. * The company's capacity utilization currently stands at 70% to 75%.
What to do with a filing like this
Excel Industries Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Excel Industries Limited. Read the original for the full detail.